DANISH BIO – DANSK BIOTEK organizes four major plenary meetings for our members throughout the year to increase our members' knowledge regarding specific biotech topics and to facilitate networking. The events usually take place in February, May, September and November.

We also organize approximately four "saloon" meetings annually. They are small, intimate, "meet the expert" meetings with typically 6-20 participants advocating more in-depth discussion and knowledge-sharing on specific themes.

13 Feb 2024

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

  • Coming Phase I/IIa basket trial planned to include five select cancer indications
  • Study will apply Curasight’s uPAR theranostic platform approach combining diagnosis (uTRACE®) and therapy (uTREAT®)
  • First patients expected to be dosed in the beginning of 2025 with expected first efficacy data in 2025.

Copenhagen, Denmark, 13 February 2024 – Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design. The trial will investigate Curasight’s theranostic (therapeutics/diagnostics) approach by testing the diagnostic platform uTRACE® and the treatment platform uTREAT® in brain cancer (Glioblastoma), neuroendocrine tumors (NET), head-and-neck cancer (HNSCC), non-small cell lung cancer (NSCLC), and pancreatic cancer. To strengthen the Company’s capital structure and secure funding for the acceleration of clinical activities, Curasight intends to launch a rights issue during the first quarter of 2024. Details of the rights issue are to be announced in a separate press release immediately following this release.

“We believe the theranostic approach using radiopharmaceuticals to both diagnose and treat certain types of cancer has the potential to provide important new solutions to clinicians and patients,” said Curasight’s CEO, Ulrich Krasilnikoff. “We have already achieved important results in most of the indications with our diagnostics platform uTRACE as well as positive preclinical results in brain and lung cancer using our therapeutic solution uTREAT. By launching this basket trial, we can accelerate development of both uTRACE and uTREAT (theranostic) in parallel and potentially have therapeutic efficacy data already during 2025.” The trial of five cancer types in parallel takes advantage of our theranostic platform working across tumor types as uPAR is expressed in the majority of all solid cancers. This also increases the likelihood of entering into partnering with pharma companies”.



    If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact ps@danskbiotek.dk or +45 7172 1114

    Copyright 2024 DANISH BIO – DANSK BIOTEK. All rights reserved.